Skip to content

Clinical Study on Electroacupuncture Treatment for Chemotherapy-Induced Peripheral Neuropathy Based on Deep Learning and Multimodal Information Fusion.

Clinical Study on Electroacupuncture Treatment for Chemotherapy-Induced Peripheral Neuropathy Based on Deep Learning and Multimodal Information Fusion.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001882
Enrollment
Unknown
Registered
2025-10-11
Start date
2025-10-15
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced peripheral neuropathy

Interventions

Early Acupuncture Group:Under the same acupuncture manipulation conditions, the intervention time points were the 7th day, the 4th day, and the 1st day before the initiation of chemotherapy.
Delayed Acupuncture Group:Under the same acupuncture manipulation conditions, the intervention time points were on the 1st day, the 4th day, and the 7th day after the initiation of chemotherapy.
Waiting group:The "blank control" without acupuncture intervention, with the intervention measures being only "standardized medical care and observation procedures"

Sponsors

Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients newly diagnosed with stage II or III colorectal cancer (American Joint Committee on Cancer 8th edition staging); planning to receive oxaliplatin-based chemotherapy regimens (e.g., treatment course =6 cycles, oxaliplatin dose =85mg/m²); with an Eastern Cooperative Oncology Group performance status score of 0-1; who have signed informed consent forms, voluntarily participate in the study, and cooperate with bioelectric signal collection.

Exclusion criteria

Exclusion criteria: 1) Previous treatment with chemotherapy drugs such as paclitaxel, vinca alkaloids, and platinum-based agents (excluding oxaliplatin) that may cause chemotherapy-induced peripheral neuropathy; 2) Severe organ dysfunction (end-stage renal disease, severe heart failure) or uncontrolled infections; 3) Local infection, inflammation, or tumor infiltration at the acupuncture site; 4) Current use of antidepressants (e.g., duloxetine), antiepileptics (e.g., gabapentin), or neurotrophic drugs (e.g., mecobalamin); 5) Coagulation disorders ; 6) Use of non-removable electronic devices or metal implants (e.g., pacemakers); 7) Presence of consciousness disorders, psychiatric disorders, or communication impairments that prevent completion of scale assessments; 8) Pregnant or lactating women; 9) Concurrent diabetic peripheral neuropathy, HIV-associated neuropathy, or other severe non-chemotherapy-related neuropathies; 10) Receipt of any form of acupuncture or electroacupuncture within 30 days prior to enrollment. The most common symptom of hemorrhoids is painless bleeding during bowel movements..The most common symptom of hemorrhoids is painless bleeding during bowel movements.

Design outcomes

Primary

MeasureTime frame
Incidence of Chemotherapy-induced peripheral neuropathy;

Secondary

MeasureTime frame
Incidence of Chemotherapy-induced peripheral neuropathy at Week 2 and Week 4.;European Organisation for Research Quality of Life Questionnaire and Treatment of Cancer-Chemotherapy-Induced Peripheral Neuropathy 20-item scale score;European Organisation for Research and Treatment of Cancer score;

Countries

China

Contacts

Public ContactYufeng Xie

Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine

yufengxie1624@gzucm.edu.cn13760387089

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026